Table 4.
Summary of non-randomized histology-agnostic studies examined in this article. Data extracted from clinicaltrials.gov (October, 2018).
| Name | NCT Number | Enrollment | Start | End | Condition (Disease) |
|---|---|---|---|---|---|
| MATCH M1 | NCT02465060 S1 | 6452 E,* | 2015 A,+ | 2022 E,+ | Advanced Refractory Solid Tumors, Lymphomas, Multiple Myeloma |
| WINTHER M1 | NCT01856296 S2,C1 | 200 E,* | 2013 A,+ | 2018 E,+ | Metastatic Cancer, Advanced Malignancies |
| MOSCATO M2 | NCT01566019 S2 | 1050 E,* | 2011 A,+ | 2019 E,+ | Metastatic Solid Tumors (Any Localization) |
| TAPUR M2 | NCT02693535 S3,C2 | 2980 E,* | 2016 A,+ | 2021 E,+ | Advanced Solid Tumors, Lymphomas (Non-Hodgkin), Multiple Myeloma |
A Actual; E Estimated (expected); * Number of participants; + Year (of respective date). M1 Intervention model: Parallel Assignment. M2 Intervention model: Single Group Assignment. S1 Sponsor: National Cancer Institute (NCI). S2 Sponsor: Gustave Roussy. S3 Sponsor: American Society of Clinical Oncology (ASCO). C1 Collaborator: NGS performed by Foundation Medicine. C2 Collaborators: AstraZeneca, Bayer, Bristol-Myers Squibb, Eli Lilly and Company, Genentech Inc., Merck Sharp & Dohme Corp., and Pfizer.